CENTOCOR, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: 1.2K

Market Cap: -

Website: http://www.centocor.com

Clinical Trials

A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo capsules
Drug: Placebo injections
Drug: Methotrexate capsules
Biological: Golimumab 50 mg injections
Biological: Golimumab 100 mg injections

First Posted Date: 2005-12-13

Last Posted Date: 2014-09-05

Lead Sponsor: Centocor, Inc.

Target Recruit Count: 637

Registration Number: NCT00264537

A Long-term Safety Study of Infliximab (Remicade)

Completed

Conditions: Arthritis, Rheumatoid
Crohn Disease
Psoriasis

Interventions: Drug: Infliximab (Remicade)

First Posted Date: 2005-12-06

Last Posted Date: 2014-03-18

Lead Sponsor: Centocor, Inc.

Target Recruit Count: 2971

Registration Number: NCT00261976

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: Intetumumab
Drug: Placebo
Drug: Dacarbazine

First Posted Date: 2005-10-30

Last Posted Date: 2013-08-19

Lead Sponsor: Centocor, Inc.

Target Recruit Count: 144

Registration Number: NCT00246012

A Safety and Efficacy Study for Infliximab (Remicade) With Methotrexate in Patients With Early Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2005-10-12

Last Posted Date: 2011-05-19

Lead Sponsor: Centocor, Inc.

Target Recruit Count: 607

Registration Number: NCT00236028

A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis

Phase 2

Completed

Conditions: Psoriasis

First Posted Date: 2005-10-03

Last Posted Date: 2011-06-09

Lead Sponsor: Centocor, Inc.

Target Recruit Count: 249

Registration Number: NCT00230529

A Study of the Safety and Efficacy of Infliximab (Remicade) in Pediatric Patients With Crohn's Disease

Phase 3

Completed

Conditions: Crohn Disease

First Posted Date: 2005-09-21

Last Posted Date: 2011-05-17

Lead Sponsor: Centocor, Inc.

Target Recruit Count: 112

Registration Number: NCT00207675

A Study of the Safety and Efficacy of Infliximab (Remicade) in Subjects With Fistulizing Crohn's Disease

Phase 3

Completed

Conditions: Crohn Disease

First Posted Date: 2005-09-21

Last Posted Date: 2010-04-27

Lead Sponsor: Centocor, Inc.

Target Recruit Count: 306

Registration Number: NCT00207766

An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: MTX
Drug: Golimumab
Drug: Infliximab
Drug: Placebo

First Posted Date: 2005-09-21

Last Posted Date: 2012-10-18

Lead Sponsor: Centocor, Inc.

Target Recruit Count: 172

Registration Number: NCT00207714

A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2005-09-21

Last Posted Date: 2012-04-23

Lead Sponsor: Centocor, Inc.

Target Recruit Count: 249

Registration Number: NCT00207727

A Study of Infliximab (Remicade) in Patients With Ankylosing Spondylitis.

Phase 3

Completed

Conditions: Ankylosing Spondylitis

First Posted Date: 2005-09-21

Last Posted Date: 2011-05-17

Lead Sponsor: Centocor, Inc.

Target Recruit Count: 279

Registration Number: NCT00207701

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy